INOZYME PHARMA INC. -

Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

06 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business Updates

15 Aug 2022 06:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures

26 Jul 2022 06:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

19 Jul 2022 15:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Partnership with Rady Children’s Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases

16 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer

07 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference

01 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights

10 May 2022 06:30:01 By Nasdaq GlobeNewswire

Inozyme Pharma to Present at Upcoming Investor Conferences

03 May 2022 06:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market

14 Apr 2022 07:16:50 By Nasdaq GlobeNewswire

Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency

12 Apr 2022 06:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Present at the 21st Annual Needham Virtual Healthcare Conference

06 Apr 2022 06:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency

04 Apr 2022 06:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business Highlights

15 Mar 2022 16:24:24 By Nasdaq GlobeNewswire

Inozyme Pharma Strengthens Management Team with Two Executive Appointments

08 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Present at Cowen 42nd Annual Health Care Conference

01 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency

15 Nov 2021 06:30:01 By Nasdaq GlobeNewswire

Inozyme Pharma to Present at Upcoming Investor Conferences

11 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Third Quarter 2021 Financial Results and Provides Business Highlights

09 Nov 2021 15:05:03 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program at the ASBMR 2021 Annual Meeting

04 Oct 2021 06:30:00 By Nasdaq GlobeNewswire